ALLMedicine™ Thymic Tumors Center

Jun 25th, 2022 - Thymic malignancies represent a heterogeneous group of rare thoracic cancers, which are classified according to the World Health Organization histopathologic classification, that distinguishes thymomas from thymic carcinomas. Data regarding the bi...

Apr 11th, 2022 - Thymic tumors are rare tumors, but represent the most common tumors of the anterior mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to spread to the pleura. In first line therapy, combination chemotherapy pro...

Mar 16th, 2022 - This review summarizes the changes in the 5th edition of the WHO Classification of Endocrine and Neuroendocrine Tumors that relate to the thyroid gland. The new classification has divided thyroid tumors into several new categories that allow for a...

Feb 16th, 2022 - This study aimed to evaluate the therapeutic efficacy of thymectomy through a subxiphoid video-thoracoscopic approach with double elevation of the sternum compared with traditional intercostal uniportal video-assisted thoracic surgery for stage I-...

Dec 21st, 2021 - Sebaceous differentiation is an unexpected and unusual phenomenon in the normal thymic gland. Among thymic tumors, sebaceous glands are a relatively common component of mediastinal teratomas but are exceedingly rare in other neoplasms of thymic or...

Nov 20th, 2012 - Neuroendocrine bronchial and thymic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.|2012|Öberg K,Hellman P,Ferolla P,Papotti M, ,|therapeutic use,diagnosis,pathology,therapy,diagnosis,pathology,therapy,diagnosis,p...

May 9th, 2008 - Neuroendocrine bronchial and thymic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up.|2008|Oberg K,Jelic S, ,|diagnosis,epidemiology,pathology,therapy,diagnosis,epidemiology,pathology,therapy,diagnosis,epidemiology,patho...

Apr 11th, 2022 - Thymic tumors are rare tumors, but represent the most common tumors of the anterior mediastinum. Thymoma has an indolent course in advanced disease and has the propensity to spread to the pleura. In first line therapy, combination chemotherapy pro...

Oct 8th, 2020 - Rationale: Even though the World Health Organization (WHO) histological classification and Masaoka-Koga staging system are currently the most widely used, some studies have validated alternative pathologic classifications, as the one proposed by S...

Jul 5th, 2018 - Background: (18)F FLT, a thymidine analog, has uptake in tumors that correlates with proliferative rates and may be an early predictor of tumor response. Due to uptake in inflammatory tissues, routinely used (18)F FDG PET/CT is often unable to dis...

Jun 3rd, 2014 - Thymic carcinomas are particularly more concerning due to their aggressive metastatic nature and shorter overall survival, in comparison to their lesser-malignant thymoma counterparts. This necessitates the need for systemic therapy. Due to the pa...

Aug 28th, 2009 - The aim of the present study is to investigated the genetic alterations in tumor samples of a series of all WHO-defined subtypes of thymoma patients using high resolution microarray- comparative genomic hybridization (CGH) followed by hierarchical...

Dec 20th, 2020 - Jonathan Riess, MD, MS, Assistant Professor of Medicine, Hematology and Oncology, UC Davis Comprehensive Cancer Center, discusses PD-L1 expression in a thymoma tissue microarray. As PD-1 and PD-L1 antibodies have demonstrated benefit in other tum...

Dec 5th, 2020 - Pharmaceutical companies are investing billions of dollars in a new age of oncology. The more than 900 cancer medications in the pipelines at drug companies and academic institutions constitute nearly 40% of all the drugs under development, accord...

Jun 1st, 2014 - Lab mouse Researchers say they’ve found a way to target myeloid-derived suppressor cells (MDSCs) while sparing other immune cells. In preclinical experiments, the team showed they could deplete MDSCs—and shrink tumors—using peptide antibodies.